JPH1149673A - Cancer specific medicine - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a cancer specific medicine having a strong treating effect to carcinoma, but no side effect, hence which can be used without hesitation. SOLUTION: The medicine is obtained by including p-hydroxybenzaldehyde as an active ingredient. The medicine can be provided, for example, as an aqueous solution containing p-hydroxybenzaldehyde singly, an aqueous solution containing p-hydroxybenzaldehyde and syrup, a tablet prepared by using vehicle powder, and an injection prepared, for example, by dissolving p- hydroxybenzaldehyde in an isotonic sodium chloride solution.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a specific cancer drug which can be used without side effects.

[0002]

2. Description of the Related Art Various studies have been made on derivatives of benzaldehyde as anticancer agents. This is because benzaldehyde, which is a highly irritating organic solvent, cannot be used as a drug, but can be used by making it a water-soluble solid derivative, and its drug efficacy can be expected. However, such derivatives do not exhibit their efficacy unless the binding site is degraded in the patient. Therefore, it is not only uneconomical, but also has a limited use and dosage, and thus a limited efficacy.

[0003]

Therefore, the present inventor has proposed:
Various studies have been made on the anticancer properties of benzoic acid, but in order to obtain a desired drug effect, a very large dose was required. The present invention provides a smaller dose than such benzoic acid,
You can get more efficient medicinal effects without side effects,
It is an object to provide a new cancer specific medicine.

[0004]

Means for Solving the Problems The present inventors have focused on a relatively hydrophilic and low molecular weight p-hydroxybenzaldehyde which is a benzaldehyde compound which is solid at ordinary temperature and completed the present invention.

[0005] The cancer specific medicine of the present invention contains p-hydroxybenzaldehyde as an active ingredient.
In both cases of oral administration and injection, remarkable efficacy is observed when p-hydroxybenzaldehyde is administered at 1 g / day or less, for example, about 5 to 500 mg / day.

The cancer specific drug of the present invention may be formed into a solution using p-hydroxybenzaldehyde alone as an aqueous solution, a solution prepared by mixing it with a syrup, or a tablet using a powdery carrier. It may be formed into an injection solution by, for example, dissolving in physiological saline.

[0007]

【Example】

Example 1 The effects of benzoic acid, p-hydroxybenzoic acid and p-hydroxybenzaldehyde on malignant tumor cell growth were tested as follows. Cells used: × 63 (mouse myeloma cells) Culture conditions 1.1 × 10 ⁴ cells / well / cultured in 200 microliter medium for 24 hours (in the medium, benzoic acid, p-hydroxybenzoic acid and p-hydroxybenzaldehyde were used). 25.000 mM, 12.500 m respectively
M, 6.250 mM, 3.125 mM, 1.562 mM, 0.7
81 mM, 0.391 mM and 0.195 mM were added).
Three culture tubes were used per concentration of each additive. 2. Add 0.5 μCi / well of ³ H-thymidine, and further culture for 18 hours to incorporate ³ H-thymidine into the cells during DNA synthesis. 3. Cells that have taken up ³ H-thymidine are counted as radioactivity with a liquid scintillation counter, and the number is expressed as counts per minute. The results obtained are shown in Table 1 and FIG. 1 (average and standard deviation of the results obtained in three culture tubes).

[0008]

[Table 1]

As is apparent from Table 1 and FIG. 1, only p-hydroxybenzaldehyde shows a remarkable inhibition of tumor cell proliferation at 12.5 mM or more. In this case, it can be confirmed by microscopic observation that the cells are dead. In contrast, benzoic acid has no effect at 25 mM or less.

Example 2 The effects of the present invention were confirmed by the following cases. Case 1 A 61-year-old man was diagnosed with lung cancer at the age of 55, and was treated with sodium benzoate (30 g after 2 g / day).
g / day), and the course was good. However, in April of this year, about 6 years later, the patient had nausea after taking the drug. Cause discomfort,
Due to anorexia, cough, and bloody sputum, she started taking p-hydroxybenzaldehyde later in the month. The dose of the drug was increased from 70 mg / day to 30
0 mg / day, but 2 weeks after starting the oral administration,
Blood sputum stopped, and 4 weeks later, remarkable effects were observed, such as improvement in chest discomfort.

Case 2 A 38-year-old woman who developed right subcostal pain at the age of 32,
A gallbladder ultrasonography confirmed a gallbladder neoplasm, and the patient was diagnosed with gallbladder cancer in addition to the subjective symptoms. Later, ultrasonographic findings were normalized, but subjective symptoms persisted, albeit mildly.
-Changed to hydroxybenzaldehyde (drug dose: 70 mg / day, increased to 300 mg / day)
One month later, right subcostal pain subsided and disappeared three months later.

[0012]

By the administration of the drug of the present invention, the growth of malignant tumors can be prevented without side effects, and not only the cancerous disease is relieved, but also it is finally cured.

[Brief description of the drawings]

FIG. 1 is a graph showing the results of testing the effects of benzoic acid, p-hydroxybenzoic acid and p-hydroxybenzaldehyde on malignant tumor cell growth.

Claims (1)

[Claims] 1. A cancer specific medicine comprising p-hydroxybenzaldehyde as an active ingredient.